Free Trial

Janux Therapeutics (JANX) 10K Form and Latest SEC Filings 2026

Janux Therapeutics logo
$14.33 -0.09 (-0.62%)
Closing price 04:00 PM Eastern
Extended Trading
$14.60 +0.27 (+1.88%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Janux Therapeutics SEC Filings & Recent Activity

Janux Therapeutics (NASDAQ:JANX) has submitted 308+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Janux Therapeutics's financial statements. The most recent filing was a Form SCHEDULE 13G submitted on April 29, 2026.

Form 4
Janux Therapeutics, Inc. Reports Ownership Change on Feb. 4, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Janux Therapeutics Files Current Report on Apr. 28, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Janux Therapeutics Files Annual Report on Feb. 26, 2026

The 10-K contains Janux Therapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Janux Therapeutics SEC Filing History

Browse Janux Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/29/2026 4:30 PM
Janux Therapeutics (1817713) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G
04/29/2026 4:31 PM
Janux Therapeutics (1817713) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G
04/28/2026 3:56 PM
Janux Therapeutics (1817713) Filer
Form ARS
04/28/2026 4:02 PM
Janux Therapeutics (1817713) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/28/2026 3:15 PM
Janux Therapeutics (1817713) Filer
Form DEF 14A
04/13/2026 3:05 PM
Janux Therapeutics (1817713) Subject
Meyer Andrew Hollman (1864159) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/26/2026 3:47 PM
Janux Therapeutics (1817713) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/26/2026 3:32 PM
Janux Therapeutics (1817713) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/26/2026 3:10 PM
Janux Therapeutics (1817713) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/09/2026 5:43 AM
Janux Therapeutics (1817713) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
02/06/2026 3:23 PM
Janux Therapeutics (1817713) Subject
Prosight Management, LP (1617201) Filed by
Form SCHEDULE 13G
02/04/2026 7:00 PM
Go William (2108554) Reporting
Janux Therapeutics (1817713) Issuer
Form 3
Initial statement of beneficial ownership of securities  
02/04/2026 7:01 PM
Go William (2108554) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 3:08 PM
Janux Therapeutics (1817713) Subject
Meyer Andrew Hollman (1864159) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2026 3:30 PM
Janux Therapeutics (1817713) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2026 8:09 AM
FMR LLC (315066) Filed by
Janux Therapeutics (1817713) Subject
Form SCHEDULE 13G/A
01/02/2026 8:00 PM
Dobek Maria (2032671) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 8:00 PM
Doyle Janeen Noel (2069239) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 8:00 PM
Janux Therapeutics (1817713) Issuer
McIver Zachariah (2050056) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 8:00 PM
Janux Therapeutics (1817713) Issuer
Winter Charles M. (1960264) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 8:00 PM
Campbell David Alan (1864158) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 8:00 PM
DiRaimondo Thomas (2005618) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 8:00 PM
Janux Therapeutics (1817713) Issuer
Meyer Andrew Hollman (1864159) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 3:42 PM
Janux Therapeutics (1817713) Subject
Robinson Byron (1914899) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/03/2025 7:00 PM
Janux Therapeutics (1817713) Issuer
Meyer Andrew Hollman (1864159) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 4:15 PM
Janux Therapeutics (1817713) Subject
Robinson Byron (1914899) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/01/2025 3:20 PM
Janux Therapeutics (1817713) Subject
Meyer Andrew Hollman (1864159) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2025 7:00 PM
Janux Therapeutics (1817713) Issuer
Meyer Andrew Hollman (1864159) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/07/2025 11:10 AM
JANUS HENDERSON GROUP PLC (1274173) Filed by
Janux Therapeutics (1817713) Subject
Form SCHEDULE 13G/A
11/06/2025 3:39 PM
Janux Therapeutics (1817713) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 3:10 PM
Janux Therapeutics (1817713) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/30/2025 7:00 PM
Janux Therapeutics (1817713) Issuer
Meyer Andrew Hollman (1864159) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/28/2025 3:16 PM
Janux Therapeutics (1817713) Subject
Meyer Andrew Hollman (1864159) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/19/2025 4:06 PM
Janux Therapeutics (1817713) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 10:26 AM
JANUS HENDERSON GROUP PLC (1274173) Filed by
Janux Therapeutics (1817713) Subject
Form SCHEDULE 13G/A
08/12/2025 8:05 AM
Adage Capital Management, L.P. (1535978) Filed by
Janux Therapeutics (1817713) Subject
Form SCHEDULE 13G/A
07/17/2025 6:54 PM
BlackRock, Inc. (2012383) Filed by
Janux Therapeutics (1817713) Subject
Form SCHEDULE 13G
06/13/2025 6:30 PM
Janux Therapeutics (1817713) Issuer
Kung Winston (1666963) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 6:30 PM
Janux Therapeutics (1817713) Issuer
Simson Jake (1863094) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 6:30 PM
Janux Therapeutics (1817713) Issuer
McNulty Alana B. (1606086) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 6:30 PM
Hernday Natasha (1780547) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 6:30 PM
Gujrathi Sheila (1575202) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 6:30 PM
DOBMEIER ERIC (1202785) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 6:30 PM
CAPPS VICKIE L (1248190) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 6:30 PM
Barrett Ronald W (1326330) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 6:33 PM
Janux Therapeutics (1817713) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 7:00 PM
Doyle Janeen Noel (2069239) Reporting
Janux Therapeutics (1817713) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 7:02 PM
Doyle Janeen Noel (2069239) Reporting
Janux Therapeutics (1817713) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/14/2025 11:25 AM
JANUS HENDERSON GROUP PLC (1274173) Filed by
Janux Therapeutics (1817713) Subject
Form SCHEDULE 13G/A
05/08/2025 3:30 PM
Janux Therapeutics (1817713) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Janux Therapeutics SEC Filings - Frequently Asked Questions

Janux Therapeutics (JANX) has submitted 308+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

Janux Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Janux Therapeutics's financial statements page.

The most recent filing was a Form SCHEDULE 13G submitted on April 29, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:JANX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners